---
title: A study to find how well LY3884961 works and how safe it is in participants with Parkinson’s disease
euct_id: 2024-519587-40-00
status: Not authorised
sponsor: Prevail Therapeutics Inc.
canonical_url: "https://parkinsonspathways.com/trials/eu/2024-519587-40-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2024-519587-40-00"
ctis_last_updated: "2025-06-17T03:34:15.336844557"
source: EU Clinical Trials Information System (CTIS)
---
# A study to find how well LY3884961 works and how safe it is in participants with Parkinson’s disease

**EU CT Number:** [2024-519587-40-00](https://euclinicaltrials.eu/ctis-public/view/2024-519587-40-00)

## Key Facts

- **Status:** Not authorised
- **Sponsor:** Prevail Therapeutics Inc.
- **Start Date:** 2025-06-30
- **Completion Date:** 2031-02-28
- **Conditions:** Parkinson’s Disease with at Least One GBA1 Mutation, Disease Parkinson's
- **Interventions:** LY3884961

## Member States

Trial is authorized in 1 member state: Netherlands.

## Sites (1)

- Centre for Human Drug Research, Leiden, Netherlands

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson’s Disease with at Least One GBA1 Mutation; Disease Parkinson's
Age groups: elderly 65+, adults 18-64
Sex: male, female
Includes a vulnerable population.

Period: Treatment Period
During the first year, patients will be evaluated for the effect of LY3884961 on safety, tolerability, immunogenicity, biomarkers, and selected efficacy.
Arms:
  - Cohort 1: patients who received the Dose Level 1 of LY3884961
  - Cohort 2: patients to receive the Dose Level 2 of LY3884961

Period: Follow up Period
Patients will continue to be followed up for an additional 4 years to continue to monitor safety, selected biomarker, and efficacy parameters.
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2024-519587-40-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2024-519587-40-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2024-519587-40-00*